

AACR Special Conference on
Endometrial Cancer: Transforming Care Through Science
November 16-18, 2023 | Boston, MA

AACR American Association for Cancer Research

Current as of November 15, 2023

Short Talks Selected from Proffered Abstracts

PR-01 **Highlighting the combined effects of BMI and polygenic risk score on endometrial cancer risk**. Tracy A. O'Mara. QIMR Berghofer Medical Research Institute, Brisbane, QueensIalnd, Australia.

PR-02 **Proteomic profiling of endometrial carcinomas**. Dawn Cochrane. BC Cancer, Vancouver, British Columbia, Canada.

PR-03 **The Combination of the Glucagon Like Peptide-1 Receptor Agonist Semaglutide and the Progestin Levonorgestrel is Highly Effective in Preclinical Studies of Endometrial Cancer**. Kimberly K. Leslie. The University of New Mexico, Albuquerque, New Mexico, United States.

PR-04 **CD73 is a novel repressor of mutant β-catenin oncogenic activity in endometrial cancer**. Rebecca M. Hirsch. UNC Chapel Hill, Chapel Hill, North Carolina, United States.

PR-05 **Patients with Endometrial Cancer and Benign Gynecologic Conditions Exhibit Unique Vaginal and Rectal Microbiomes**. Nicole R. Jimenez. University of Arizona - College of Medicine- Phoenix, Phoenix, Arizona, United States.

PR-06 **ARID1A/B mutations retarget mSWI/SNF chromatin remodeler activity and define a spectrum of dedifferentiation in endometrial carcinoma**. Jessica D. St. Laurent. Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States.

PR-07 Patient **derived organoide as a model to study estrogen mediated endometrial cancer**. Breanna BW. Jeffcoat. University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States.

PR-08 **Location, location, location: Why cellular localization of mutant β-catenin matters in endometrial cancer**. Molly L. Parrish. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.



AACR Special Conference on
Endometrial Cancer: Transforming Care Through Science
November 16-18, 2023 | Boston, MA

AACR American Association for Cancer Research

Poster Session A (To be presented on November 16 from 7:30- 9 p.m. ET)

Disparities

A001 **Tracking the Relationship between Accrual and Comorbidities in Clinical TRrial Enrollment (TRACE)**.
Kemi Doll. University of Washington, Seattle, Washington, United States.

A002A **In-silico screening of race-specific endometrial cancer methylation markers using machine learning techniques**. Huma Asif. Northwestern University, Chicago, Illnois, United States.

A002B **Decomposing racial and ethnic disparities in endometrial cancer survival**.
Jordyn Brown. University of North Carolina, Chapel Hill, North Carolina, United States.

A002C **TP53 mutational landscape in non-cancerous endometrium during the lifespan of Black and White individuals**.
Eric Rios-Doria. University of Washington, Seattle, Washington, United States.

A003 **The cause behind the COST – exploring qualitative and quantitative aspects of financial toxicity in women diagnosed with advanced/recurrent Endometrial cancer**. Sarah Ackroyd. University of Chicago, Chicago, Illnois, United States.

A004 **Performance of the laparoscopic hysterectomy readmission score among diverse women with endometrial cancer**.
Ashley Felix. The Ohio State University, Columbus, Ohio, United States.

A005 **Single Nuclei Analysis of Uterine Serous Carcinoma Reveals Racial Differences in Immune Signaling**.
Grace Foley. Northwestern, Chicago, Illinois, United States.

A006 **Intermittent fasting in combination with PD-inhibitor treatment as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer**.
Jennifer Haag. University of North Carolina, Durham, North Carolina, United States.

A007 **Addressing obesity's impact on the PTEN mutant endometrium**.
Hilary Skalski. Michigan State University, Grand Rapids, Michigan, United States.

A008 **Mitochondrial depletion and metabolic reprogramming is a novel phenotype of Lynch syndrome-related endometrial carcinogenesis**.
Mikayla Bowen. MD Anderson Cancer Center, Houston, Texas, United States.

Targeted Therapeutics

A009 **The Combination of the Glucagon Like Peptide-1 Receptor Agonist Semaglutide and the Progestin Levonorgestrel is Highly Effective in Preclinical Studies of Endometrial Cancer**. Kimberly Leslie. The University of New Mexico, Albuquerque, New Mexico, United States.

A010 **Genomic landscape of somatic alterations identified in endometrial cancer using liquid biopsy**.

Stephanie Lheureux. Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

A012 **Role of stromal CD10 expression in progression of endometrial and endometriosis-associated cancers**. Huda Atiya. University of Pittsburgh, Pittsburgh, Pennsylvania, United States.

A013 **Multiplexed live-cell imaging for drug responses in patient-derived organoid models of endometrial cancer**. Kaitriana Colling. University of Iowa, Iowa City, Iowa, United States.

A014 **NXP800, a novel, small molecule GCN2 kinase activator, demonstrates potent single-agent activity in ARID1A and ARID1B-deficient endometrial cancer xenograft models**. Ramez Eskander. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego Rebecca and John Moores Cancer Center, La Jolla, Calfornia, United States.

A015 **Prevalence and significance of common molecular alterations in Tp53-mutated Uterine Serous Carcinoma**. Olivier Harismendy. Zentalis Pharmaceuticals, San Diego, Calfornia, United States.

A016 **A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer**. Lauren Dockery. Stephenson Cancer Center, Oklahoma University Health, Oklahoma City, Oklahoma, United States.

Prevention and Screening

A017 **Autologous patient-derived organoid-immune cell co-culture platform for therapeutics discovery in high-grade endometrial cancer.** Charlie Chung. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States.

A018 **Highlighting the combined effects of BMI and polygenic risk score on endometrial cancer risk**. Tracy O'Mara. QIMR Berghofer Medical Research Institute, Brisbane, QueensIalnd, Australia.

A019 **Pilot study of daily exemestane in patients with Endometrial Intraepithelial Neoplasia (EIN) or grade 1 endometrial cancer**. Britt Erickson. University of Minnesota, Minneapolis, Minnesota, United States.

A020 **Detecting Cardiovascular Disease Risk in Early-Stage Endometrial Cancer Survivors: Preliminary Evidence of Pulse Wave Velocity and Social Vulnerability Index**. Lauren Bates-Fraser. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.

A021 **Assessing the reproducibility crisis in vaginal microbiome studies for clinical applications in endometrial cancer**. Dollina Dodani. University of British Columbia, Vancouver, British Columbia, Canada.



AACR Special Conference on
Endometrial Cancer: Transforming Care Through Science
November 16-18, 2023 | Boston, MA

AACR American Association for Cancer Research

Poster Session B (To be presented on November 17 from 6:30-8:00 p.m. ET)

Molecular Mechanisms

B001 **CD73 is a novel repressor of mutant β-catenin oncogenic activity in endometrial cancer**. Rebecca M. Hirsch. UNC Chapel Hill, Chapel Hill, North Carolina, United States.

B002 **ARID1A Loss Activates MAPK Signaling via DUSP4 Downregulation: A Mechanistic Insight in Endometrial Carcinoma**. Jayaprakash Mandal. Johns hopkins University School of Medicine, Baltimore, Marlyand, United States.

B003 **Patient derived organoide as a model to study estrogen mediated endometrial cancer**. Breanna BW. Jeffcoat. University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States.

B004 **Investigating loss of ARID1A protein on endometrial cancer progression through the destabilization of adherens junctions**. Savannah E. Wright. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.

B005 **Proteomic profiling of endometrial carcinomas**. Dawn Cochrane. BC Cancer, Vancouver, British Columbia, Canada.

B006 **Mutant PPP2R1A Induces the Expression and Secretion of IGFBP2 to Promote Uterine Serous Carcinoma Metastasis**. Terrance James Haanen. University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States.

B007 **Investigation of the mechanism of PADI2 regulation by the FBXW7 tumor suppressor**. Chandra Mani Kafle. National Human Genome Research Institute, National Institutes of Health, Bethesda, Marlyand, United States.

B008 **Modeling radiation sensitivity in patient-derived organoid models of endometrial cancer**. Sofia Gabrilovich. University of Iowa, Iowa City, Iowa, United States.

Targeted Therapeutics

B009 **Global Expression Analysis of Endometrial Cancer Cells in Response to Progesterone Identifies New Therapeutic Targets**. Kristina Thiel. University of Iowa, Iowa City, iowa, United States.

B010 **Response to treatment with nab-sirolimus among patients with primary uterine tumors: A subgroup analysis from AMPECT**. Norma A. Palma. Aadi Bioscience, Pacific Palisades, Calfornia, United States.

B011 **Phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2 (PRECISION I)**. Debra L. Richardson. Stephenson Cancer Center, OU Health, Oklahoma City, Oklahoma, United States.

B012 **Application of shallow whole genome sequencing to identify therapeutic opportunities in p53abn endometrial cancers**. Amy Jamieson. University of British Columbia, Vancouver, British Columbia, Canada.

B013 **Folate receptor alpha (FRa) expression and correlation with other molecular alterations in high grade serous endometrial cancer (EC)**. Rebecca L. Porter. Dana-Farber Cancer Institute, Boston, Massachusetts, United States.

B014 **Patient-derived organoid models for drug screening in molecular subtypes of endometrial cancer**. Dongli Liu. UNSW, Australia, NSW, Australia.

B015 **A Novel Cluster 3 Endometrial Cancer PDX Model to Test Hormone Therapy Regimens**. Kimberly K. Leslie. The University of New Mexico, Albuquerque, NM, United States.

B016 **Novel Curcumin Analogues as Therapies for Endometrial Cancer with TP53 Mutations**. Kimberly K.Leslie. The University of New Mexico, Albuquerque, NM, United States.

Other

B017 **Disease Free Survival As a Predictor of Overall Survival in Patients with High-Risk Endometrial Cancer Receiving Adjuvant Chemotherapy**. Vimalanand S. Prabhu. Merck & Co., Inc., Rahway, New Jersey, United States.

B018 **MYC is sufficient to generate mid-life high-grade serous ovarian and serous endometrial carcinomas in a BRCA wild type p53-R270H mouse model**. Alexandra Blackman. Medical University of South Carolina, Charleston, South Carolina, United States.

B019 **Assessing CirculatingTumOur Dna As A Prognostic Biomarker In Endometrial Cancer (The CODEC Study)**. Rachel Delahunty. Epworth Healthcare, Peter MacCallum Cancer, The Royal Women's Hospital, Melbourne, Australia.

B020 **A clinically-relevant orthotopic endometrial carcinosarcoma mouse model using human patient-derived organoids**. Megan Gorman. Northwell, Queens, New York, United States.

B021 **Early onset uterine corpus cancer incidence rates and 5-year relative survival by histologic subtype and race/ethnicity among women aged 20-49 years**. Akemi T. Wijayabahu. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Marlyand, United States.

B022 **Conversion from Minimally Invasive surgical approaches to open surgery among endometrial cancer patients in a national cancer patients' registry**. Ilana Chefetz. Mercer University, Macon, Georgia, United States.

Immune Landscape

B023 **The role of ribosomal protein L22 in regulating the immune landscape in mismatch repair deficient endometrial cancers**. Macy L. Osborne. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.

B024 **Immune exhaustion and reversal of progestin-related immune modulation in adaptive resistance to levonorgestrel intrauterine device for treatment of atypical hyperplasia and early endometrial cancer**. Mikayla B. Bowen. MD Anderson Cancer Center, Houston, Texas, United States.

B025 **IL6 signaling in pre-malignant obese endometrium and endometrial cancer**. Qian Zhang. UT MD Anderson Cancer Center, Houston, Texas, United States.

B026 **Substratification of mismatch repair deficient (MMRd) endometrial cancers can provide prognostic and predictive refinement**. Amy Jamieson. University of British Columbia, Vancouver, British Columbia, United States.

B027 **Patients with Endometrial Cancer and Benign Gynecologic Conditions Exhibit Unique Vaginal and Rectal Microbiomes**. Nicole R. Jimenez. University of Arizona - College of Medicine- Phoenix, Phoenix, Arizona, United States.

Molecular Mechanisms

B028 **Epithelial-specific loss of PIK3R1 in a murine model results in endometrial hyperplasia**. Shannon K. Harkins. Michigan State University, Grand Rapids, Michigan, United States.

B029 **ARID1A/B mutations retarget mSWI/SNF chromatin remodeler activity and define a spectrum of dedifferentiation in endometrial carcinoma**. Jessica D. St. Laurent. Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States.

B030 **DNA methylation profiling identifies subset of low-grade endometrial neoplasms with poor response to progestin therapy**. Lawrence H. Lin. Brigham and Women's Hospital - Harvard Medical School, Boston, Massachusetts, United States.

B031 **High risk no specific molecular profile' (HR-NSMP) endometrial cancer can be stratified into three subgroups based on tumor grade and estrogen receptor status with differing clinicopathologic characteristics and outcomes**. Andrea Neilson. Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.

B032 **Use of patient-derived organoids to model tumor evolution in response to chemotherapy**. Kristina Thiel. University of Iowa, Omaha, Iowa, United States.

B033 **Functional characterization of ALK5 (TGFBR1) mutations in endometrial cancer**. Eun-Jeong Yu. NHGRI/NIH, Bethesda, Marlyand, United States.

B034 **Location, location, location: Why cellular localization of mutant β-catenin matters in endometrial cancer**. Molly L. Parrish. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.

B035 **Evidence for CD73 loss promoting cancer cell stemness via metabolic reprogramming in endometrial cancer**. Emily M. Rabjohns. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.